Recombinant coagulation factor VIIa
Use of Recombinant Factor VIIa in Obstetrics
... Postpartum acquired haemophilia A, characterized by postpartum development of an inhibitor against FVIII, constitutes 7-21% of acquired haemophilia A cases and is a rare but serious complication of pregnancy associated ...
14
Comparison of 3-Factor Prothrombin Complex Concentrate and Low-Dose Recombinant Factor VIIa for Warfarin Reversal
... The administration of coagulation factors is associated with thromboembolic events. In our study groups, the inci- dence of thromboembolic events was equal in both groups. Safaoui et al. reported no thromboembolic ...
7
An in vitro evaluation of standard rotational thromboelastography in monitoring of effects of recombinant factor VIIa on coagulopathy induced by hydroxy ethyl starch
... blood, coagulation variables remained unchanged when assessed with INTEG, but were markedly affected when assessed with ...the coagulation in the INTEG and therefore insensitive to rFVIIa as rFVIIa ...
6
Recombinant activated factor VIIa and hemostasis in critical care: a focus on trauma
... Because of the off-label use of rFVIIa in trauma, the appropriate dosing and repeat dosing is currently unknown. The dosage of rFVIIa in the trauma literature varies from 40 to 212 µ g/kg (Table 1) [12-14,17-22,32]. The ...
6
Optimal use of recombinant factor VIIa in the control of bleeding episodes in hemophilic patients
... at coagulation factors render the infusion of coagulation factor concentrates ineffective, and alternative means must be used to achieve ...hemostasis. Recombinant factor VIIa ...
11
Clinical experiences and current evidence for therapeutic recombinant factor VIIa treatment in nontrauma settings
... tissue factor at sites such as atheromatous plaques in patients with ischemic heart disease might precipitate clinically relevant coagulation and ...maximal coagulation from the effect of rFVIIa ...
8
Failure of recombinant factor VIIa in a patient with severe polymicrobial sepsis and postoperative uncontrolled intraabdominal bleeding
... A 54 year old man presented in the emergency depart- ment of our hospital with a three weeks history of fever, shivering, abdominal discomfort and watery, unbloody diarrhoea. The patient's medical history was otherwise ...
6
Recombinant factor VIIa for uncontrollable bleeding in patients with extracorporeal membrane oxygenation: report on 15 cases and literature review
... Willebrand factor abnormalities induced by extracorporeal circulation could trigger acquired von Willebrand syndrome and could explain, at least in part, the elevated bleeding rate in these patients ...[2,4]. ...
10
The utility of recombinant factor VIIa as a last resort in trauma
... Over the last decade, rFVIIa has been explored as a potential treatment for many coagulopathic states other than congenital conditions and hemophilias [7,11,24] . Theoretically, rFVIIa seems to be an appealing option ...
6
Recombinant activated factor VIIa for the treatment of bleeding in major abdominal surgery including vascular and urological surgery: a review and meta analysis of published data
... with coagulation factor concentrates for which no evidence of efficacy can be derived from controlled studies, therapy algorithms considering the severity of bleeding, the patient's general health, and the ...
11
Overview of the use of recombinant factor VIIa in children
... downstream coagulation factor with amplification at each step, ultimately leading to the conversion of soluble fibrino- gen into insoluble fibrin and the formation of a fibrin ...vitro coagulation, ...
8
The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor
... via Factor VIIa-dependent activation of Factor X, but direct proof has not been available for the participation of tissue factor in this ...of recombinant Factor VIIa ...
7
Thromboembolic risks of recombinant factor VIIa Use in warfarin-associated intracranial hemorrhage: a case–control study
... activated factor capable of direct binding to tissue factor suggest it may achieve faster hemostasis, PCC contains all vitamin-K dependent coagulation factors and may be a more efficacious agent for ...
7
Pediatric Off-label Use of Recombinant Factor VIIa
... received recombinant factor VIIa for off- label ...receiving recombinant factor VIIa were disseminated intravascular coagulation/sepsis (28), surgical bleeding (19), ...
9
Intrapulmonary Recombinant Factor VIIa for Diffuse Alveolar Hemorrhage in Children
... despite intravenous acyclovir treatment. Eleven days after admission, he had difficulty in breathing, coughing, and hemoptysis. The patient was intubated, and fresh blood spurted from the endotracheal tube. UPN4 was ...
7
Tissue factor as an initiator of coagulation and inflammation in the lung
... Of note, besides in its traditional cell-associated form, TF antigen and procoagulant activity have also been detected in cell-free plasma [7]. Circulating TF resides in microparticles that can be shed from leukocytes, ...
9
Neutrophil activation by the tissue factor/Factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome
... tissue factor (TF) expression in neutrophils contributes to respiratory burst, trophoblast injury, and pregnancy loss in mice treated with ...on coagulation, but potently inhibits TF/Factor ...
10
Use of human factor VIIa in the treatment of two hemophilia A patients with high titer inhibitors
... with Factor VIIa the circumference of the muscle decreased and joint mobility increased ...given Factor VIIa concurrent with tranexamic acid in association with the extraction of two primary ...
7
Activation of Coagulation Factor V by a Platelet Protease
... to Factor V a in order to bind to a high affinity platelet surface site and participate in prothrombin ...of Factor V and a Factor V activator. We find that the Factor V released when ...
10
Recombinant epidermal growth factor-like domain-1 from coagulation factor VII functionalized iron oxide nanoparticles for targeted glioma magnetic resonance imaging
... study, recombinant epidermal growth factor-like domain-1, derived from human coagulation factor VII, was conjugated to iron oxide nanoparticles (IONPs) for targeted glioma magnetic resonance ...
10